

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

Original Issue Date (Created):	7/1/2002
Most Recent Review Date (Revised):	2/12/2021
Effective Date:	7/1/2021

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Powered negative pressure therapy systems should be used as part of a comprehensive wound care program that includes attention to other factors that impact wound healing such as diabetes control, nutritional status, relief of pressure, etc.

INITIATION OF A POWERED NEGATIVE PRESSURE WOUND THERAPY (NPWT):

An initial therapeutic trial of not less than 2 weeks using a powered negative pressure wound therapy (NPWT) system, as part of a comprehensive wound care program that includes controlling factors such as diabetes, nutrition, relief of pressure, etc., may be considered **medically necessary** in the following indications:

- Chronic (> 30 days) stage III or IV pressure ulcers that have failed to heal despite optimal wound care when there is high-volume drainage that interferes with healing and/or when standard dressings cannot be maintained due to anatomic factors, **or**
- Traumatic or surgical wounds where there has been a failure of immediate or delayed primary closure **and** there is exposed bone, cartilage, tendon, or foreign material within the wound **or**
- Wounds in patients with underlying clinical conditions which are known to negatively impact wound healing, which are non-healing (at least 30 days), despite optimal wound care. Examples of underlying conditions include, but are not limited to diabetes, malnutrition, small vessel disease, and morbid obesity. Malnutrition, while a risk factor, must be addressed simultaneously with the negative pressure wound therapy.

It is not required that a patient be homebound to receive nursing services in the patient’s home for wound care using NPWT.

NPWT will be denied at any time as **not reasonable and necessary** if one or more of the following are present:

- The presence in the wound of necrotic tissue with eschar, if debridement is not attempted;

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

- Osteomyelitis within the vicinity of the wound that is not concurrently being treated with intent to cure;
- Cancer present in the wound;
- The presence of an open fistula to an organ or body cavity within the vicinity of the wound.

Therapeutic trials of powered NPWT systems for the treatment of other acute or chronic wounds except as noted above are considered **not medically necessary**.

CONTINUATION OF POWERED NPWT:

Continuation of the powered NPWT system, as part of a comprehensive wound care program, may be considered **medically necessary** following an initial 2-week therapeutic trial if the treatment trial has resulted in documented objective improvements in the wound, and if there is ongoing objective improvement during subsequent treatment. Objective improvements in the wound should include the development and presence of healthy granulation tissue, progressive wound contracture and decreasing depth, and/or the commencement of epithelial spread from the wound margins.

NPWT may be considered **medically necessary** when continuation of treatment is ordered beyond discharge to the home setting.

Continuation of the powered NPWT system is considered **not medically necessary** when any of the following occurs:

- The therapeutic trial or subsequent treatment period has not resulted in documented objective improvement in the wound, **OR**
- The wound has developed evidence of wound complications contraindicating continued NPWT, **OR**
- The wound has healed to an extent that either grafting can be performed or the wound can be anticipated to heal completely with other wound care treatments.

Note: Continuation of healing during use of the NPWT system should be monitored on a monthly basis.

Note: Complete healing of a wound would normally be anticipated if all bone, cartilage, tendons, and foreign material were completely covered, healthy granulation were present to within 5 mm of the surface, and the wound edges were reduced to 2 cm in width or diameter.

NON-POWERED NPWT

Use of non-powered NPWT systems for the treatment of acute or chronic wounds is considered **investigational**. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

Cross-references:

- MP-1.017** Bio-Engineered Skin and Soft Tissue Substitutes
- MP-2.033** Recombinant and Autologous Platelet-Derived Growth Factors as a Treatment of Wound Healing and Other Non-Orthopedic Conditions.
- MP-2.070** Hyperbaric Oxygen Pressurization
- MP-4.028** Wound and Burn Care and Specialized Treatment Centers
- MP-6.026** Durable Medical Equipment (DME) and Supplies
- MP-8.001** Physical Medicine and Specialized Physical Medicine Treatments (Outpatient)

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross and subject to benefit variations as discussed in Section VI below. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual MP-1.01.16, Negative Pressure Wound Therapy in the Outpatient Setting. The FEP Medical Policy Manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

III. DESCRIPTION/BACKGROUND

[TOP](#)

Negative pressure wound therapy (NPWT) consists of the use of a negative pressure or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue and wound healing. The devices may also be used as an adjunct to surgical therapy or as an alternative to surgery in a debilitated patient.

Management

The management and treatment of chronic wounds, including decubitus ulcers, remain a treatment challenge. Most chronic wounds will heal only if the underlying cause, i.e., venous stasis, pressure, infection, etc., is addressed. In addition, cleaning the wound to remove nonviable tissue, microorganisms, and foreign bodies is essential to create the optimal conditions for either re-epithelialization (i.e., healing by secondary intention) or preparation for wound closure with skin grafts or flaps (i.e., healing by primary intention). Therefore, debridement, irrigation, whirlpool treatments, and wet-to-dry dressings are common components of chronic wound care.

Negative pressure wound therapy (NPWT) consists of the use of a negative pressure therapy or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue. The devices may be used as an adjunct to

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

surgical therapy or as an alternative to surgery in a debilitated patient. Although the exact mechanism has not been elucidated, it is hypothesized that negative pressure contributes to wound healing by removing excess interstitial fluid, increasing the vascularity of the wound, reducing edema, and/or creating beneficial mechanical forces that lead to cell growth and expansion.

A non-powered (mechanical) NPWT system has also been developed; one device is the Smart Negative Pressure (SNaP) Wound Care System. This device is portable and lightweight (3 oz.) and can be worn underneath clothing. This system consists of a cartridge, dressing, and strap; the cartridge acts as the negative pressure source. The system is reported to generate negative pressure levels similar to other NPWT systems. This system is fully disposable.

The focus of this document is on use of NPWT in the outpatient setting. It is recognized that patients may begin using the device in the inpatient setting as they transition to the outpatient setting.

Regulatory Status

Negative pressure therapy or suction devices cleared by the U.S. Food and Drug Administration (FDA) for the purpose of treating chronic wounds include, but are not limited to: Vacuum Assisted Closure® Therapy (V.A.C., also known as negative pressure wound therapy; KCI); Versatile 1™ (V1) Wound Vacuum System (Blue Sky Medical), RENASYS™ EZ PLUS (Smith & Nephew), Foryou NPWT NP32 Device (Foryou Medical Electronics), and PICO Single Use Negative Pressure Wound Therapy System (Smith & Nephew).

Portable systems include the RENASYS™ GO (Smith & Nephew), XLR8 PLUS (Genadyne Biotechnologies), extriCARE® 2400 NPWT System (Devon Medical), the V.A.C. Via™ (KCI), and the PICO™ Single-Use Negative Pressure Wound Therapy System (Smith & Nephew). The Prevena™ Incision Management System (KCI) is designed specifically for closed surgical incisions.

A nonpowered NPWT device, the SNaP® Wound Care System from Spiracur, is a class II device requiring notification to market but not having FDA premarket approval. In 2009, it was cleared for marketing by FDA through the 510(k) (K081406) and is designed to remove small amounts of exudate from chronic, traumatic, dehisced, acute, or subacute wounds and diabetic and pressure ulcers.

No NPWT device has been cleared for use in infants and children.

In November 2009, FDA issued an alert concerning complications and deaths associated with NPWT systems. An updated alert was issued in February 2011.

FDA product code: OMP.

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

IV. RATIONALE

[TOP](#)

Summary of Evidence

For individuals who have diabetic lower-extremity ulcers or amputation wounds who receive outpatient negative pressure wound therapy (NPWT), the evidence includes randomized controlled trials (RCTs) and a systematic review of RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. There was a higher rate of wound healing and fewer amputations with NPWT, although the studies were at risk of bias due to lack of blinding. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have chronic pressure ulcers who receive outpatient NPWT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. All trials are of low quality and at high risk of bias. In addition, most study populations were treated in inpatient settings. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have lower-extremity ulcers due to venous insufficiency who receive outpatient NPWT, the evidence includes 1 RCT and a systematic review. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. A single RCT in patients with nonhealing leg ulcers who were treated with skin grafts found a faster rate of healing with NPWT when used in the inpatient setting. No studies were identified on the effectiveness of NPWT as a primary treatment for leg ulcers or for use of NPWT in the outpatient setting. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have burn wounds who receive outpatient NPWT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. An interim report of an RCT evaluating NPWT in partial-thickness burns, summarized in a Cochrane review, did not permit conclusions on the efficacy of NPWT in partial-thickness burns. A separate RCT comparing NPWT with split-skin grafts in patients with full-thickness burns did not show differences in graft take and wound epithelialization. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have traumatic or surgical wounds who receive outpatient NPWT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. There are limited data on NPWT as a primary treatment of partial-thickness burns. One RCT found no benefit of NPWT on graft take and wound epithelialization in patients with full-thickness burns. NPWT showed no benefit in the treatment of patients with surgical wounds or skin grafts healing by primary intention, and a systematic review of NPWT for traumatic and surgical wounds found no differences between standard dressing and NPWT for any wound outcome measure. However, 1

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

small RCT has suggested that prophylactic NPWT may reduce the number of dressing changes and pain when used in an outpatient setting. Additional study in larger samples is needed to evaluate this outcome measure. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have any wound type (acute or nonhealing) who receive portable single-use outpatient NPWT, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. The evidence includes an RCT of the PICO Single Use Negative Pressure Wound Therapy System, an RCT of the nonpowered Smart Negative Pressure (SNaP) Wound Care System, and a pseudorandomized study of the Prevena Incision Management System. The PICO device was studied in an adequately powered but unblinded RCT of combined in- and outpatient use following total joint arthroplasty. Results showed some benefits that approached statistical significance. Further study in an outpatient setting is needed. One study with the SNaP nonpowered Wound Care System showed noninferiority to a vacuum-assisted closure device. However, interpretation of this trial is limited by a high loss to follow-up and lack of a control group treated with dressings. These studies are insufficient to draw conclusions about its efficacy. Well-designed comparative studies with larger numbers of patients are needed to determine the effects of the technology with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

V. DEFINITIONS

[TOP](#)

ATMOSPHERIC PRESSURE is the pressure exerted by the weight of the atmosphere, also known as barometric pressure.

COMPREHENSIVE WOUND CARE PROGRAM includes a minimum of all the following general measures:

- Documentation in the patient’s medical record of evaluation, care and wound measurements by a licensed medical professional; and
- Application of dressings to maintain a moist wound environment; and
- Debridement of necrotic tissue when present; and
- Evaluation of and provision for adequate nutritional and vascular status

GRANULATING TISSUE refers to formation of granule-like projections on the internal surface of the wound that represents the outgrowth of new capillaries, bringing a rich blood supply to the wound, promoting healing.

PRESSURE (DECUBITUS) ULCER is a type of wound that forms as a result of prolonged pressure against areas of the skin. This is commonly seen over the bony prominences, such as sacrum and

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

heels, in bedridden and/or wheelchair confined individuals. Pressure ulcers are classified into four stages (and an unstageable category), to signify the degree of skin damage:

Stage I- Intact skin with non-blanchable redness of a localized area usually over a bony prominence. Darkly pigmented skin may not have visible blanching; its color may differ from the surrounding area.

Stage II- Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed, without slough. May also present as an intact or open/ruptured serum-filled blister.

Stage III- Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle is not exposed. Slough may be present but does not obscure the depth of tissue loss. May include undermining and tunneling.

Stage IV- Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be present on some parts of the wound bed. Often include undermining and tunneling.

Unstageable- Full thickness tissue loss in which the base of the ulcer is covered by slough (yellow, tan, gray, green or brown) and/or eschar (tan, brown or black) in the wound bed. (Until enough slough and/or eschar is removed to expose the base of the wound, the true depth, and therefore stage, cannot be determined.)

VASCULARITY is the state of blood vessel development and functioning in an organ or tissue.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member's individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member's benefit information or contact Capital BlueCross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered:

HCPCS Code	Description
A9272	Mechanical wound suction, disposable, includes dressing, all accessories and components, each

Covered when medically necessary:

CPT Codes®						
97605	97606	97607	97608			

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

HCPCS Codes	Description
A6550	Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories
A7000	Canister, disposable, used with suction pump, each
A7001	Canister, nondisposable, used with suction pump, each
E2402	Negative pressure wound therapy electrical pump, stationary or portable
K0743	Suction pump, home model, portable, for use on wounds
K0744	Absorptive wound dressing for use with suction pump, home model, portable, pad size 16 sq. in or less
K0745	Absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 sq. in but less than or equal to 48 sq. in
K0746	Absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 sq. in

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

ICD-10-CM Diagnosis Code	Description
E10.621	Type 1 diabetes mellitus with foot ulcer
E10.621	Type 1 diabetes mellitus with foot ulcer
E10.622	Type 1 diabetes mellitus with other skin ulcer
E11.621	Type 2 diabetes mellitus with foot ulcer
E11.622	Type 2 diabetes mellitus with other skin ulcer
E13.621	Other specified diabetes mellitus with foot ulcer
E13.622	Other specified diabetes mellitus with other skin ulcer
I70.231	Atherosclerosis of native arteries of right leg with ulceration of thigh
I70.232	Atherosclerosis of native arteries of right leg with ulceration of calf
I70.233	Atherosclerosis of native arteries of right leg with ulceration of ankle
I70.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot
I70.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot
I70.241	Atherosclerosis of native arteries of left leg with ulceration of thigh
I70.242	Atherosclerosis of native arteries of left leg with ulceration of calf
I70.243	Atherosclerosis of native arteries of left leg with ulceration of ankle
I70.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot
I70.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot
I83.011	Varicose veins of right lower extremity with ulcer of thigh
I83.012	Varicose veins of right lower extremity with ulcer of calf
I83.013	Varicose veins of right lower extremity with ulcer of ankle
I83.014	Varicose veins of right lower extremity with ulcer of heel and midfoot
I83.015	Varicose veins of right lower extremity with ulcer other part of foot
I83.021	Varicose veins of left lower extremity with ulcer of thigh
I83.022	Varicose veins of left lower extremity with ulcer of calf
I83.023	Varicose veins of left lower extremity with ulcer of ankle
I83.024	Varicose veins of left lower extremity with ulcer of heel and midfoot
I83.025	Varicose veins of left lower extremity with ulcer other part of foot
I87.311	Chronic venous hypertension (idiopathic) with ulcer of right lower extremity
I87.312	Chronic venous hypertension (idiopathic) with ulcer of left lower extremity
I87.313	Chronic venous hypertension (idiopathic) with ulcer of bilateral lower extremity
L89.003	Pressure ulcer of unspecified elbow, stage 3
L89.004	Pressure ulcer of unspecified elbow, stage 4
L89.013	Pressure ulcer of right elbow, stage 3
L89.014	Pressure ulcer of right elbow, stage 4
L89.023	Pressure ulcer of left elbow, stage 3

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

L89.024	Pressure ulcer of left elbow, stage 4
L89.103	Pressure ulcer of unspecified part of back, stage 3
L89.104	Pressure ulcer of unspecified part of back, stage 4
L89.113	Pressure ulcer of right upper back, stage 3
L89.114	Pressure ulcer of right upper back, stage 4
L89.123	Pressure ulcer of left upper back, stage 3
L89.124	Pressure ulcer of left upper back, stage 4
L89.133	Pressure ulcer of right lower back, stage 3
L89.134	Pressure ulcer of right lower back, stage 4
L89.143	Pressure ulcer of left lower back, stage 3
L89.144	Pressure ulcer of left lower back, stage 4
L89.153	Pressure ulcer of sacral region, stage 3
L89.154	Pressure ulcer of sacral region, stage 4
L89.203	Pressure ulcer of unspecified hip, stage 3
L89.204	Pressure ulcer of unspecified hip, stage 4
L89.213	Pressure ulcer of right hip, stage 3
L89.214	Pressure ulcer of right hip, stage 4
L89.223	Pressure ulcer of left hip, stage 3
L89.224	Pressure ulcer of left hip, stage 4
L89.303	Pressure ulcer of unspecified buttock, stage 3
L89.304	Pressure ulcer of unspecified buttock, stage 4
L89.313	Pressure ulcer of right buttock, stage 3
L89.314	Pressure ulcer of right buttock, stage 4
L89.323	Pressure ulcer of left buttock, stage 3
L89.324	Pressure ulcer of left buttock, stage 4
L89.43	Pressure ulcer of contiguous site of back, buttock and hip, stage 3
L89.44	Pressure ulcer of contiguous site of back, buttock and hip, stage 4
L89.503	Pressure ulcer of unspecified ankle, stage 3
L89.504	Pressure ulcer of unspecified ankle, stage 4
L89.513	Pressure ulcer of right ankle, stage 3
L89.514	Pressure ulcer of right ankle, stage 4
L89.523	Pressure ulcer of left ankle, stage 3
L89.524	Pressure ulcer of left ankle, stage 4
L89.603	Pressure ulcer of unspecified heel, stage 3
L89.604	Pressure ulcer of unspecified heel, stage 4
L89.613	Pressure ulcer of right heel, stage 3
L89.614	Pressure ulcer of right heel, stage 4
L89.623	Pressure ulcer of left heel, stage 3

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

L89.624	Pressure ulcer of left heel, stage 4
L89.813	Pressure ulcer of head, stage 3
L89.814	Pressure ulcer of head, stage 4
S31.100D	Unspecified open wound of abdominal wall, right upper quadrant without penetration into peritoneal cavity, subsequent encounter
S31.100S	Unspecified open wound of abdominal wall, right upper quadrant without penetration into peritoneal cavity, sequela
S31.101D	Unspecified open wound of abdominal wall, left upper quadrant without penetration into peritoneal cavity, subsequent encounter
S31.101S	Unspecified open wound of abdominal wall, left upper quadrant without penetration into peritoneal cavity, sequela
S31.102D	Unspecified open wound of abdominal wall, epigastric region without penetration into peritoneal cavity, subsequent encounter
S31.102S	Unspecified open wound of abdominal wall, epigastric region without penetration into peritoneal cavity, sequela
S31.103D	Unspecified open wound of abdominal wall, right lower quadrant without penetration into peritoneal cavity, subsequent encounter
S31.103S	Unspecified open wound of abdominal wall, right lower quadrant without penetration into peritoneal cavity, sequela
S31.104D	Unspecified open wound of abdominal wall, left lower quadrant without penetration into peritoneal cavity, subsequent encounter
S31.104S	Unspecified open wound of abdominal wall, left lower quadrant without penetration into peritoneal cavity, sequela
S31.105D	Unspecified open wound of abdominal wall, periumbilic region without penetration into peritoneal cavity, subsequent encounter
S31.105S	Unspecified open wound of abdominal wall, periumbilic region without penetration into peritoneal cavity, sequela
T81.31XA	Disruption of external operation (surgical) wound, not elsewhere classified, initial encounter
T81.31XD	Disruption of external operation (surgical) wound, not elsewhere classified, subsequent encounter
T81.32XA	Disruption of internal operation (surgical) wound, not elsewhere classified, initial encounter
T81.32XD	Disruption of internal operation (surgical) wound, not elsewhere classified, subsequent encounter
T81.33XA	Disruption of traumatic injury wound repair, initial encounter
T81.33XD	Disruption of traumatic injury wound repair, subsequent encounter
T81.42XA	Infection following a procedure, deep incisional surgical site, initial encounter
T81.42XD	Infection following a procedure, deep incisional surgical site, subsequent encounter
T81.49XA	Infection following a procedure, other surgical site, initial encounter
T81.49XD	Infection following a procedure, other surgical site, subsequent encounter

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

IX. REFERENCES

[TOP](#)

1. U.S. Food and Drug Administration. *Executive Summary Breast Implant Special Topics*. March 2019. <https://www.fda.gov/media/122956/download>. Accessed February 12, 2021.
2. Lee KT, Mun GH. Updated evidence of acellular dermal matrix use for implant-based breast reconstruction: a meta-analysis. *Ann Surg Oncol*. Feb 2016;23(2):600-610. PMID 26438439
3. McCarthy CM, Lee CN, Halvorson EG, et al. The use of acellular dermal matrices in two-stage expander/implant reconstruction: a multicenter, blinded, randomized controlled trial. *Plast Reconstr Surg*. Nov 2012;130(5 Suppl 2):57S-66S. PMID 23096987
4. Hinchcliff KM, Orbay H, Busse BK, et al. Comparison of two cadaveric acellular dermal matrices for immediate breast reconstruction: A prospective randomized trial. *J Plast Reconstr Aesthet Surg*. May 2017;70(5):568-576. PMID 28341592
5. Mendenhall SD, Anderson LA, Ying J, et al. The BREASTrial Stage II: ADM breast reconstruction outcomes from definitive reconstruction to 3 months postoperative. *Plast Reconstr Surg Glob Open*. Jan 2017;5(1):e1209. PMID 28203509
6. Liu DZ, Mathes DW, Neligan PC, et al. Comparison of outcomes using AlloDerm versus FlexHD for implant-based breast reconstruction. *Ann Plast Surg*. May 2014;72(5):503-507. PMID 23636114
7. Chang EI, Liu J. Prospective unbiased experience with three acellular dermal matrices in breast reconstruction. *J Surg Oncol*. Sep 2017;116(3):365-370. PMID 28444764
8. Pittman TA, Fan KL, Knapp A, et al. Comparison of Different Acellular Dermal Matrices in Breast Reconstruction: The 50/50 Study. *Plast Reconstr Surg*. Mar 2017;139(3):521-528. PMID 28234811
9. Dikmans RE, Negenborn VL, Bouman MB, et al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial. *Lancet Oncol*. Feb 2017;18(2):251-258. PMID 28012977
10. Barber FA, Burns JP, Deutsch A, et al. A prospective, randomized evaluation of acellular human dermal matrix augmentation for arthroscopic rotator cuff repair. *Arthroscopy*. Jan 2012;28(1):8-15. PMID 21978432
11. Bellows CF, Smith A, Malsbury J, et al. Repair of incisional hernias with biological prosthesis: a systematic review of current evidence. *Am J Surg*. Jan 2013;205(1):85-101. PMID 22867726
12. Roth JS, Zachem A, Plymale MA, et al. Complex ventral hernia repair with acellular dermal matrices: clinical and quality of life outcomes. *Am Surg*. Feb 1 2017;83(2):141-147. PMID 28228200
13. Bellows CF, Shadduck P, Helton WS, et al. Early report of a randomized comparative clinical trial of Strattice reconstructive tissue matrix to lightweight synthetic mesh in the repair of inguinal hernias. *Hernia*. Apr 2014;18(2):221-230. PMID 23543334

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

14. *Fleshman JW, Beck DE, Hyman N, et al. A prospective, multicenter, randomized, controlled study of non-cross-linked porcine acellular dermal matrix fascial sublay for parastomal reinforcement in patients undergoing surgery for permanent abdominal wall ostomies. Dis Colon Rectum. May 2014;57(5):623-631. PMID 24819103*
15. *Santema TB, Poyck PP, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. Feb 11 2016;2:CD011255. PMID 26866804*
16. *Martinson M, Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care. Oct 2016;25(Sup10):S8-S17. PMID 27681811*
17. *Guo X, Mu D, Gao F. Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis. Int J Surg. Apr 2017;40:1-7. PMID 28232031*
18. *Steinberg JS, Edmonds M, Hurley DP, Jr., et al. Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc. Jan-Feb 2010;100(1):73-77. PMID 20093548*
19. *Kirsner RS, Warriner R, Michela M, et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol. Aug 2010;146(8):857-862. PMID 20713816*
20. *Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. Jun 2003;26(6):1701-1705. PMID 12766097*
21. *Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. Adv Skin Wound Care. Jan 2015;28(1):17-20. PMID 25407083*
22. *Zelen CM, Orgill DP, Serena T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. Apr 2017;14(2):307-315. PMID 27073000*
23. *Zelen CM, Orgill DP, Serena TE, et al. An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial. International wound journal. Oct 2018;15(5):731-739. PMID 29682897*
24. *Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen. Nov 12 2015;23(6):891-900. PMID 26297933*
25. *Campitiello F, Mancone M, Della Corte A, et al. To evaluate the efficacy of an acellular Flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial. Updates Surg. Dec 2017;69(4):523-529. PMID 28497218*

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

26. Brigido SA, Boc SF, Lopez RC. *Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. Orthopedics. Jan 2004;27(1 Suppl):s145-149. PMID 14763548*
27. Reyzelman A, Crews RT, Moore JC, et al. *Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J. Jun 2009;6(3):196-208. PMID 19368581*
28. Reyzelman AM, Bazarov I. *Human acellular dermal wound matrix for treatment of DFU: literature review and analysis. J Wound Care. Mar 2015;24(3):128; 129-134. PMID 25764957*
29. Brigido SA. *The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. Sep 2006;3(3):181-187. PMID 16984575*
30. Walters J, Cazzell S, Pham H, et al. *Healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers. Eplasty. Mar 2016;16:e10. PMID 26933467*
31. Cazzell S, Vayser D, Pham H, et al. *A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair Regen. May 2017;25(3):483-497. PMID 28544150*
32. Sanders L, Landsman AS, Landsman A, et al. *A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Manage. Sep 2014;60(9):26-38. PMID 25211605*
33. DiDomenico L, Landsman AR, Emch KJ, et al. *A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. Wounds. Jul 2011;23(7):184-189. PMID 25879172*
34. Frykberg RG, Cazzell SM, Arroyo-Rivera J, et al. *Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis. J Wound Care. Jul 2016;25 Suppl 7:S18-25. PMID 27410467*
35. Kavros SJ, Dutra T, Gonzalez-Cruz R, et al. *The use of PriMatrix, a fetal bovine acellular dermal matrix, in healing chronic diabetic foot ulcers: a prospective multicenter study. Adv Skin Wound Care. Aug 2014;27(8):356- 362. PMID 25033310*
36. Karr JC. *Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf). Adv Skin Wound Care. Mar 2011;24(3):119-125. PMID 21326023*
37. Niezgodna JA, Van Gils CC, Frykberg RG, et al. *Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. Jun 2005;18(5 Pt 1):258-266. PMID 15942317*
38. Uccioli L, Giurato L, Ruotolo V, et al. *Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized*

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

controlled clinical trial with long-term follow-up. The international journal of lower extremity wounds. Jun 2011;10(2):80-85. PMID 21693443

39. O'Meara S, Cullum N, Nelson EA et al. Compression for venous leg ulcers.. *Cochrane Database Syst Rev*, 2012 Nov 16;11:CD000265. PMID 23152202
40. Mostow EN, Haraway GD, Dalsing M, et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. *J Vasc Surg*. May 2005;41(5):837-843. PMID 15886669
41. Romanelli M, Dini V, Bertone M, et al. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. *Int Wound J*. Mar 2007;4(1):3-7. PMID 17425543
42. Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. *Adv Skin Wound Care*. Jan 2010;23(1):34-38. PMID 20101114
43. Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. *Int Wound J*. Apr 2013;10(2):132-137. PMID 23506344
44. Cazzell S. A Randomized Controlled Trial Comparing a Human Acellular Dermal Matrix Versus Conventional Care for the Treatment of Venous Leg Ulcers.. *Wounds*, 2019 Feb 6;31(3). PMID 30720443
45. Carsin H, Ainaud P, Le Bever H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five-year single-center experience with 30 patients. *Burns*. Jun 2000;26(4):379-387. PMID 10751706
46. Lagus H, Sarlomo-Rikala M, Bohling T, et al. Prospective study on burns treated with Integra(R), a cellulose sponge and split-thickness skin graft: comparative clinical and histological study--randomized controlled trial. *Burns*. Dec 2013;39(8):1577-1587. PMID 23880091
47. Branski LK, Herndon DN, Pereira C, et al. Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. *Crit Care Med*. Nov 2007;35(11):2615-2623. PMID 17828040
48. Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. *J Burn Care Rehabil*. Jan-Feb 2003;24(1):42-48. PMID 12543990
49. Amani H, Dougherty WR, Blome-Eberwein S. Use of Transcyte and dermabrasion to treat burns reduces length of stay in burns of all size and etiology. *Burns*. Nov 2006;32(7):828-832. PMID 16997480
50. Fivenson DP, Scherschun L, Cohen LV. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. *Plast Reconstr Surg*. Aug 2003;112(2):584-588. PMID 12900618
51. Baldursson BT, Kjartansson H, Konradsdottir F, et al. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

porcine small intestine submucosa: a noninferiority study. Int J Low Extrem Wounds. Mar 2015;14(1):37-43. PMID 25759413

52. Still J, Glat P, Silverstein P, et al. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. *Burns. Dec 2003;29(8):837-841. PMID 14636761*
53. Brown-Etris M, Milne CT, Hodde JP. An extracellular matrix graft (Oasis wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial.. *J Tissue Viability, 2018 Dec 5;28(1). PMID 30509850*
54. Lazic T, Falanga V. Bioengineered skin constructs and their use in wound healing. *Plast Reconstr Surg. Jan 2011;127 Suppl 1:75S-90S. PMID 21200276*
55. Saffle JR. Closure of the excised burn wound: temporary skin substitutes. *Clin Plast Surg. Oct 2009;36(4):627-641. PMID 19793557*
56. National Institute for Health and Care Excellence (NICE). *Diabetic Foot Problems: Prevention and Management [NG19]. 2019; <https://www.ncbi.nlm.nih.gov/books/NBK553608/>. Accessed February 12, 2021.*
57. Centers for Medicare & Medicaid Services (CMS). *Fact Sheet: CMS finalizes Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System changes for 2019. <https://www.cms.gov/newsroom/fact-sheets/cms-finalizes-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center>. Accessed February 12, 2021.*
58. Emily Haesler (Ed.). *European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Quick Reference Guide. EPUAP/NPIAP/PPPIA: 2019. <https://www.epuap.org/pu-guidelines/>. Accessed February 12, 2021.*
59. Centers for Medicare & Medicaid Services (CMS). *Provider Compliance Tips for Negative Pressure Wound Therapy. <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/ProviderComplianceTipsforNegativePressureWoundTherapy-ICN909484.pdf>. Accessed February 12, 2021.*
60. Gethin G. *The Importance of Continuous Wound Measuring. Wounds-UK. 2006. Vol 2, No 2. <https://www.wounds-uk.com/journals/issue/6/article-details/the-importance-of-continuous-wound-measuring-1>. Accessed February 12, 2021.*
61. *International Consolidated Venous Ulcer Guideline (ICVUG) 2015.(Update of AAWC Venous Ulcer Guideline, 2005 and 2010). <https://aawconline.memberclicks.net/assets/appendix%20c%20guideline%20icvug-textformatrecommendations-final%20v42%20changessaved18aug17.pdf>. Accessed February 12, 2021.*
62. Lavery LA, Davis KE, Berriman SJ, et al. *WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Rep and Reg, January/February 2016; 24: 112-126. <https://doi.org/10.1111/wrr.12391>. Accessed February 12, 2021.*

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

63. Zens Y, Barth M, Bucher, HC, et al. Negative pressure wound therapy in patients with wounds healing by secondary intention: a systematic review and meta-analysis of randomised controlled trials. *Syst Rev*, 2020; 9, 238. <https://doi.org/10.1186/s13643-020-01476-6>. Accessed February 12, 2021.

64. Seidel D, Diedrich S, Herrle F, et al. Negative Pressure Wound Therapy vs Conventional Wound Treatment in Subcutaneous Abdominal Wound Healing Impairment: The SAWHI Randomized Clinical Trial. *JAMA Surg*. 2020; 155(6):469–478. doi:10.1001/jamasurg.2020.0414. <https://jamanetwork.com/journals/jamasurgery/fullarticle/2763979>. Accessed February 12, 2021.

65. Gestring M. Negative Pressure Wound Therapy. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated July 22, 2020. Literature review current through Jan 2021. www.uptodate.com. Accessed February 12, 2021.

66. Blue Cross Blue Shield Association Medical Policy Reference Manual. 1.01.16, Negative Pressure Wound Therapy in the Outpatient Setting February 2020.

X. POLICY HISTORY

[TOP](#)

MP 4.004	CAC 2/25/03
	CAC 3/25/03
	CAC 2/22/05
	CAC 3/29/05
	Retire Policy Use InterQual Criteria effective 7/1/06
	CAC 2/27/07
	CAC 5/27/08
	CAC 11/25/08
	CAC 11/24/09 Consensus Review
	CAC 11/30/10 Medicare Variation
	CAC 6/26/12 Consensus. FEP variation changed to reference FEP Medical Policy Manual MP-1.01.16 Negative Pressure Wound Therapy in the Outpatient Setting.
	CAC 9/24/13 Minor. Adopting BCBSA for the following changes.
	<ul style="list-style-type: none"> • Changed Vacuum Assisted Wound Closure (VAWCD) to negative pressure wound therapy (NPWT). • Added the term “powered” to existing policy statements to specify criteria is for the powered NPWT. • Added statement indicating coverage for non-powered NPWT is investigational. Previously silent on non-powered VAWCD. • Added description for chronic wounds as > 90 days

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

	<ul style="list-style-type: none"> • Added medically necessary indication for Non-healing wounds despite optimal wound care (at least 30 days) in patients with underlying clinical conditions which are known to negatively impact wound healing. • Expanded objective improvements of wound healing to include the development and presence of healthy granulation tissue, progressive wound contracture and decreasing depth, and/or the commencement of epithelial spread from the wound margins. • BCBSA Description/Background adopted. • Added definition of comprehensive wound management program. • Deleted additional description of wound care for specific types of wounds. • Deleted statement indicating The VAWCD may be considered medically necessary in the presence of a fistula, except to an organ or body cavity within the vicinity of the wound. • Added rationale section • Added policy guidelines which indicate the following -- Contraindications to the use of NPWT systems include the following conditions as noted by a November 2009 FDA alert: necrotic tissue with eschar, untreated osteomyelitis, nonenteric and unexplored fistulas, malignancy in the wound, exposed nerve, exposed anastomotic site, and exposed organ. • Deleted 2 statements related to earlier initiation of therapy. • Deleted the following statement “Use of a VAWCD may be considered medically necessary at the time of hospital discharge for the specific diagnoses listed above, and for similar surgical wounds if wound care was begun in the hospital. It is not required that a patient be homebound to receive nursing services in the patient’s home for wound care using a VAWD.” <p>Administrative code review completed.</p>
	CAC 9/30/14 Consensus review. Rationale and references updated. No changes to the policy statements.
	01/2015 -New 2015 CPT code added to the policy.
	CAC 9/29/15 Consensus review. No change to policy statements. References and rationale updated. Coding reviewed.
	04/04/16 - admin add A6550
	CAC 11/29/16 Consensus. No change to policy statements. References and rationale updated. Variation reformatting. Coding reviewed.
	Admin update 1/17/18: Medicare variations removed from Commercial Policies effective 1/1/18.
	<p>11/14/17 Minor revision. Policy statement revisions:</p> <ul style="list-style-type: none"> • Chronic stage III or IV pressure ulcers further described as > 30 days. • NPWT not reasonable and necessary criteria added.

POLICY TITLE	NEGATIVE PRESSURE WOUND THERAPY IN THE OUTPATIENT SETTING
POLICY NUMBER	MP-4.004

	<ul style="list-style-type: none"> • Added statement that NPWT may be considered medically necessary when continuation of treatment is ordered beyond discharge to the home setting. • Length of coverage criteria added. <p>Cross-Reference, Description/Background, Rationale and Reference sections updated. Coding updated. Effective 6/1/18.</p>
	7/17/18 Consensus review. No change to policy statements. Rationale condensed. References updated.
	10/1/18 Admin Update: Removed deleted ICD-10 codes and added new ICD-10 codes effective 10/1/18.
	4/23/2019 Consensus review. Policy statements remain unchanged. References updated.
	04/23/2020 Consensus review. Policy statements remain unchanged.
	2/12/2021 Minor review. Took out statement regarding nursing services. Changed frequency of monitoring from every 14 days to monthly. Took out Length of Coverage Section. Clarified non-powered by adding single-use NPWT. Deleted Policy Guidelines. Updated cross-references. No changes to coding. Updated references.
	3/23/2021: Per discussion at CAC, added back statement: It is not required that a patient be homebound to receive nursing services in the patient’s home for wound care using NPWT.
	5/24/2021: Per special CAC circulation, deleted “single-use” from INV statement and reverted sentence back to original language.

[TOP](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.